Catalog No.S1004 Synonyms: NSC 737664
Molecular Weight(MW): 244.29
Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Cited by 119 Publications
Purity & Quality Control
Choose Selective PARP Inhibitors
|Description||Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.|
|Features||Increases the efficacy of common cancer therapies such as radiation and alkylating agents.|
ABT-888 is inactive to SIRT2 (>5 μM).  ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells.  ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation.  ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. 
|In vivo||The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration.  ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation.  ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. |
|In vitro||DMSO||17 mg/mL (69.58 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03044795||Withdrawn||Drug: Veliparib||Cancer||University Medical Center Groningen|AbbVie|Dutch Cancer Society||November 2019||Phase 2|
|NCT02723864||Recruiting||Drug: Veliparib + VX-970 + Cisplatin||Neoplasms||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||August 9 2017||Phase 1|
|NCT02483104||Completed||Drug: veliparib|Drug: carboplatin|Drug: paclitaxel||Ovarian Cancer||AbbVie||July 2015||Phase 1|
|NCT01445522||Completed||Drug: ABT-888|Drug: Cyclophosphamide||Neoplasms|Lymphoma||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||December 3 2008||Phase 1|
|NCT00649207||Completed||Drug: ABT-888|Radiation: Whole Brain Radiation Therapy||Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms||AbbVie (prior sponsor Abbott)|AbbVie||March 2008||Phase 1|
|NCT00553189||Completed||Drug: ABT-888|Drug: Topotecan||Solid Tumors|Lymphomas||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||August 9 2007||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.